NCT04667897ranibizumab601macular oedemaBRVOCRVONCT04667910
…randomised, double-masked, active-controlled phase IIa trials ( NCT04667897, NCT04667910) conducted at 12 Chinese sites (2021–2022), 120 pa…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04667897 ×
NCT04667897
This institution is selected. Its supporting articles are shown below.